Edition:
United States

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

9.95USD
13 Jul 2018
Change (% chg)

$-0.10 (-1.00%)
Prev Close
$10.05
Open
$10.11
Day's High
$10.19
Day's Low
$9.90
Volume
148,691
Avg. Vol
183,827
52-wk High
$20.25
52-wk Low
$7.90

Chart for

About

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $894.46
Shares Outstanding(Mil.): 47.15
Dividend: --
Yield (%): --

Financials

  AKBA.OQ Industry Sector
P/E (TTM): -- 85.48 32.76
EPS (TTM): -3.62 -- --
ROI: -85.01 2.29 14.61
ROE: -147.39 3.86 16.34

Ex-Akebia employee jailed for night as insider trading trial starts

BOSTON A former Akebia Therapeutics Inc employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.

Jun 26 2018

CORRECTED-Ex-Akebia employee jailed for night as insider trading trial starts

BOSTON, June 26 A former Akebia Therapeutics Inc employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.

Jun 26 2018

BRIEF-Akebia Therapeutics Reports Q1 Loss Per Share $0.48

* AKEBIA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Akebia Therapeutics Announces Proposed Public Offering Of Common Stock

* AKEBIA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 22 2018

BRIEF-Akebia Therapeutics Inc Files For Potential Mixed Shelf Offering Amount Not Disclosed - SEC Filing

* AKEBIA THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; AMOUNT NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2tG5aJJ) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 12 2018

BRIEF-Akebia Therapeutics Announces Q4 Earnings Per Share $0.25

* AKEBIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Mar 12 2018

BRIEF-Akebia Therapeutics Gives Update On Vadadustat Development Program

* AKEBIA THERAPEUTICS PROVIDES UPDATE ON VADADUSTAT DEVELOPMENT PROGRAM

Feb 12 2018

Competitors

  Price Chg
Amgen, Inc. (AMGN.OQ) $195.91 +1.83
Johnson & Johnson (JNJ.N) $125.93 -1.83
Roche Holding Ltd. (ROG.S) CHF232.70 +2.25
Roche Holding Ltd. (RO.S) CHF237.80 +2.60
FibroGen Inc (FGEN.OQ) $63.90 -1.45
AstraZeneca plc (AZN.L) 5,502.00 +68.00
Astellas Pharma Inc (4503.T) ¥1,782 +18.50
GlaxoSmithKline plc (GSK.L) 1,576.00 -0.60
Bayer AG (BAYGn.DE) €93.39 +0.73
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates